semaglutide

Diabetes drugs must prove their value to payers, analysts say
Diabetes drugs must prove their value to payers, analysts say
Medical Marketing and Media
diabetes
payers
Novo Nordisk
semaglutide
Eli Lilly
Trulicity
Flag link:
Novo focuses on new obesity therapy Semaglutide
Novo focuses on new obesity therapy Semaglutide
GoInPharma
Novo Nordisk
obesity
semaglutide
Flag link:
Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?
Can Novo’s blockbuster push on obesity drug semaglutide succeed where others failed?
Endpoints
Novo Nordisk
semaglutide
obesity
Flag link:
Puma's FDA Decider And Semaglutide's Head-To-Head Battle
Puma's FDA Decider And Semaglutide's Head-To-Head Battle
Seeking Alpha
Puma Biotechnology
FDA
Novo Nordisk
Nerlynx
neratinib
semaglutide
Flag link:
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Novo Nordisk says obesity drug helps up to 13.8 percent weight loss in phase 2 trial
Reuters
Novo Nordisk
obesity
semaglutide
Flag link:
3 Tremendously Promising Diabetes Drugs Potentially on the Way
3 Tremendously Promising Diabetes Drugs Potentially on the Way
Motley Fool
diabetes
ertugliflozin
Merck
Pfizer
sotagliflozin
Sanofi
Lexicon Pharmaceuticals
semaglutide
Novo Nordisk
Flag link:
Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent
Novo Nordisk's diabetes drug semaglutide cuts heart risk by 26 percent
Yahoo/Reuters
Novo Nordisk
semaglutide
diabetes
Flag link:
Novo Nordisk notches another phase 3 success for GLP-1 drug
Novo Nordisk notches another phase 3 success for GLP-1 drug
BioPharma Dive
Novo Nordisk
diabetes
GLP-1 agonist
semaglutide
Flag link:
Novo Nordisk's weekly diabetes drug goes 5-for-5 in Phase III
Novo Nordisk's weekly diabetes drug goes 5-for-5 in Phase III
Fierce Biotech
diabetes
Novo Nordisk
semaglutide
Flag link:
Novo Nordisk's First Diabetes Pill Could Be A $10-20 Billion Super-Blockbuster
Novo Nordisk's First Diabetes Pill Could Be A $10-20 Billion Super-Blockbuster
Seeking Alpha
Novo Nordisk
diabetes
semaglutide
GLP-1 agonist
Flag link:
Novo Nordisk's PIONEER Trial Will Establish A New Frontier In Oral Anti-Diabetics
Novo Nordisk's PIONEER Trial Will Establish A New Frontier In Oral Anti-Diabetics
Seeking Alpha
Novo Nordisk
diabetes
semaglutide
Flag link:
Novo's weekly diabetes drug clears another Phase III hurdle
Novo's weekly diabetes drug clears another Phase III hurdle
Fierce Biotech
Novo Nordisk
diabetes
semaglutide
Bydureon
AstraZeneca
Flag link:
Intarcia vs. Novo: Which has the most appealing diabetes PhIII program?
Intarcia vs. Novo: Which has the most appealing diabetes PhIII program?
Fierce Pharma
Novo Nordisk
Intarcia
diabetes
ITCA-650
Merck
Januvia
semaglutide
Flag link:
Novo jumping into phase III trials for major oral diabetes candidate
Novo jumping into phase III trials for major oral diabetes candidate
BioPharma Dive
Novo Nordisk
diabetes
semaglutide
GLP-1 agonist
Flag link:
Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med
Novo Nordisk looks past blockbuster Victoza with PhIII success for weekly GLP-1 med
Fierce Pharma Marketing
Novo Nordisk
diabetes
Victoza
semaglutide
GLP-1 agonist
Flag link:
Novo Nordisk's new GLP-1 diabetes drug hits goal in trial
Novo Nordisk's new GLP-1 diabetes drug hits goal in trial
Yahoo/Reuters
Novo Nordisk
GLP-1 agonist
diabetes
semaglutide
Flag link:
Novo-Nordisk's Oral GLP-1 Diabetes Treatment: An Update
Novo-Nordisk's Oral GLP-1 Diabetes Treatment: An Update
Seeking Alpha
Novo Nordisk
diabetes
GLP-1 agonist
semaglutide
Flag link:
Novo Nordisk's Diabetes Pill Shows Promise
Novo Nordisk's Diabetes Pill Shows Promise
Seeking Alpha
diabetes
Novo Nordisk
Merrion
Emisphere
semaglutide
NN9924
Flag link:
NVO Candidate to Step into Phase III
NVO Candidate to Step into Phase III
Yahoo/Zacks
Novo Nordisk
semaglutide
diabetes
type 2 diabetes
Flag link:
NVO Candidate to Step into Phase III
NVO Candidate to Step into Phase III
Yahoo/Zacks
Novo Nordisk
semaglutide
diabetes
Flag link: